MEM Discussion, page-307

I'm sorry to have to write this but the incessant ramping needs to have some pushback:

Why Memphasys (ASX: MEM) is a Terrible Investment Right Now

1. Financial Disaster in the Making

• Burning Cash with No Revenue: Memphasys is a pre-revenue company with minimal sales, yet it continues to haemorrhage money (net losses of $2M–$4M annually).

• Dilution Risk is Extreme: The company has a history of emergency capital raises at discounted prices, destroying shareholder value. With only ~$2M–$5M in cash, another dilutive raise is imminent.

• Negative Shareholder Equity: If losses exceed raised capital, the company could be technically insolvent on paper.

2. Failed Commercialization Despite Years of Hype

• Felix™ is Going Nowhere: Despite regulatory approvals, adoption in IVF clinics is abysmal. Competitors like CooperSurgical dominate the market, leaving MEM with no meaningful revenue stream.

• No Demand for Its Product: If clinics wanted Felix™, sales would already be materializing. The silence on commercial progress suggests failure in execution.

3. Share Price is a Sinking Ship

• Stuck Near All-Time Lows: The stock is drifting at pennies with no bullish momentum—classic "zombie stock" behaviour.

• Zero Liquidity: Low trading volume means even if you buy, you may never find a buyer when you want to exit.

• Every Rally Gets Sold: Positive news leads to brief spikes followed by crashes, indicating smart money is dumping shares on retail investors.

4. The Biotech Graveyard is Full of Stocks Like MEM

• ASX Micro-Cap Biotechs Rarely Succeed: Most end up as worthless penny stocks after years of dilution and broken promises.

• No Institutional Interest: Big investors avoid MEM because it lacks revenue, scalability, and a clear path to profitability.

5. Macro Risks Make MEM Untouchable

• High Interest Rates Kill Speculative Biotechs: With capital expensive, burning cash = suicide for MEM.

• Market Sentiment is Against It: Investors are fleeing risky small-caps, leaving MEM to rot indefinitely.

Memphasys is a financial black hole—a classic example of a failed biotech bet. The stock is illiquid, unprofitable, and likely to keep diluting shareholders until it’s worthless. Unless you enjoy lighting money on fire, avoid MEM at all costs.

There are far safer and more promising stocks to invest in—this isn’t one of them.